The US Centers for Disease Control and Prevention (CDC) has reported the first case of 2019 Novel Coronavirus (2019-nCoV) in the US state of Washington following the return of a patient from China who tested positive to the virus.
Clarivate Analytics has agreed to acquire Decision Resources Group (DRG) from Piramal Enterprises in a deal valued at around $950m.
Civica Rx (Civica, Inc.) today announced it has signed a long-term agreement with Thermo Fisher Scientific to develop and manufacture medications with Civica as the owner of the regulatory pathway.
Merck has completed the acquisition of US-based biopharmaceutical company ArQule in a deal valued at around $2.7bn.
Twist Bioscience, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a collaboration with Schrödinger, a company focused on transforming the way therapeutics are discovered with a physics-based computational platform, to bring the two companies’ technology platforms together to discover new antibody therapeutics against G-protein coupled receptor (GPCR) targets.
Astellas Pharma has signed a deal worth up to $897.5m with Adaptimmune Therapeutics to co-develop and co-commercialise stem-cell derived allogeneic CAR-T and TCR T-cell therapies for cancer.
BioMotiv, a mission-driven biopharma company, and Atomwise, the leader in using artificial intelligence (AI) for small molecule discovery, today announced a strategic collaboration to co-develop therapies.
Charles River announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals and Gemphire Therapeutics closed on December 31, 2019.
Eli Lilly has agreed to acquire US-based biopharmaceutical company Dermira in an all-cash transaction valued at around $1.1bn.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.